Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Chemotherapy Induced Peripheral Neuropathy Treatment market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Chemotherapy Induced Peripheral Neuropathy Treatment market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Chemotherapy Induced Peripheral Neuropathy Treatment market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Chemotherapy Induced Peripheral Neuropathy Treatment products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Chemotherapy Induced Peripheral Neuropathy Treatment market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Chemotherapy Induced Peripheral Neuropathy Treatment development has been the leading industry trend of Chemotherapy Induced Peripheral Neuropathy Treatment market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
APX-3330, BR-297, Cannabidiol, Dimiracetam, Others |
| By Application Outlook |
Clinic, Hospital, Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Achelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Achelios Therapeutics Inc
- Advinus Therapeutics Ltd
- Apollo Endosurgery Inc
- Aptinyx Inc
- Asahi Kasei Pharma Corp
- Can-Fite BioPharma Ltd
- Celgene Corp
- DermaXon LLC
- Eisai
- Immune Pharmaceuticals Inc
- INSYS Therapeutics Inc
- Kineta Inc
- KPI Therapeutics Inc
- Krenitsky Pharmaceuticals Inc
- MAKScientific LLC
- Metys Pharmaceuticals AG
- Midatech Pharma US Inc
- Mundipharma International Ltd
- Nemus Bioscience Inc
- Neurocentrx Pharma Ltd
- Panacea Pharmaceuticals Inc
- PeriphaGen Inc
- PharmatrophiX Inc
- PledPharma AB
- Sova Pharmaceuticals Inc
- Virobay Inc
- WEX Pharmaceuticals Inc
Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Type
- APX-3330
- BR-297
- Cannabidiol
- Dimiracetam
- Others
Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Application
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 APX-3330 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 BR-297 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 Cannabidiol Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Dimiracetam Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Type
8.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Application (Consumption and Market Share)
8.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Application (Consumption and Market Share)
8.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Application (Consumption and Market Share)
8.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Achelios Therapeutics Inc
9.1.1 Achelios Therapeutics Inc Profiles
9.1.2 Achelios Therapeutics Inc Product Portfolio
9.1.3 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.1.4 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.2 Advinus Therapeutics Ltd
9.2.1 Advinus Therapeutics Ltd Profiles
9.2.2 Advinus Therapeutics Ltd Product Portfolio
9.2.3 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.2.4 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.3 Apollo Endosurgery Inc
9.3.1 Apollo Endosurgery Inc Profiles
9.3.2 Apollo Endosurgery Inc Product Portfolio
9.3.3 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.3.4 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.4 Aptinyx Inc
9.4.1 Aptinyx Inc Profiles
9.4.2 Aptinyx Inc Product Portfolio
9.4.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.4.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.5 Asahi Kasei Pharma Corp
9.5.1 Asahi Kasei Pharma Corp Profiles
9.5.2 Asahi Kasei Pharma Corp Product Portfolio
9.5.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.5.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.6 Can-Fite BioPharma Ltd
9.6.1 Can-Fite BioPharma Ltd Profiles
9.6.2 Can-Fite BioPharma Ltd Product Portfolio
9.6.3 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.6.4 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.7 Celgene Corp
9.7.1 Celgene Corp Profiles
9.7.2 Celgene Corp Product Portfolio
9.7.3 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.7.4 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.8 DermaXon LLC
9.8.1 DermaXon LLC Profiles
9.8.2 DermaXon LLC Product Portfolio
9.8.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.8.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.9 Eisai
9.9.1 Eisai Profiles
9.9.2 Eisai Product Portfolio
9.9.3 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.9.4 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.10 Immune Pharmaceuticals Inc
9.10.1 Immune Pharmaceuticals Inc Profiles
9.10.2 Immune Pharmaceuticals Inc Product Portfolio
9.10.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Performance
9.10.4 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Development and Market Status
9.11 INSYS Therapeutics Inc
9.12 Kineta Inc
9.13 KPI Therapeutics Inc
9.14 Krenitsky Pharmaceuticals Inc
9.15 MAKScientific LLC
9.16 Metys Pharmaceuticals AG
9.17 Midatech Pharma US Inc
9.18 Mundipharma International Ltd
9.19 Nemus Bioscience Inc
9.20 Neurocentrx Pharma Ltd
9.21 Panacea Pharmaceuticals Inc
9.22 PeriphaGen Inc
9.23 PharmatrophiX Inc
9.24 PledPharma AB
9.25 Sova Pharmaceuticals Inc
9.26 Virobay Inc
9.27 WEX Pharmaceuticals Inc
10 World Chemotherapy Induced Peripheral Neuropathy Treatment Market Assessment by Players
10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Unit) of Players 2014-2020
10.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Assessment of Players 2014-2020
11.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Assessment of Players 2014-2020
11.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Price Assessment of Players 2014-2020
11.1.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Assessment of Players 2014-2020
11.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Price Assessment of Players 2014-2020
11.2.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Assessment of Players 2014-2020
11.4.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Assessment of Players 2014-2020
11.4.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Price Assessment of Players 2014-2020
11.4.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries/Regions 2014-2020
12.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries/Regions 2014-2020
12.2.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries/Regions 2014-2020
12.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries/Regions 2014-2020
12.3.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries/Regions 2014-2020
12.4.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries/Regions 2014-2020
12.4.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Chemotherapy Induced Peripheral Neuropathy Treatment Sales & Revenue Forecast 2021-2026
14.1 World Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Chemotherapy Induced Peripheral Neuropathy TreatmentSales and Market Share by Regions
14.1.2 World Chemotherapy Induced Peripheral Neuropathy TreatmentRevenue and Market Share by Regions
15 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 APX-3330
15.1.2 BR-297
15.1.3 Cannabidiol
15.1.4 Dimiracetam
15.1.5 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 APX-3330
16.1.2 BR-297
16.1.3 Cannabidiol
16.1.4 Dimiracetam
16.1.5 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 APX-3330
17.1.2 BR-297
17.1.3 Cannabidiol
17.1.4 Dimiracetam
17.1.5 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 APX-3330
18.1.2 BR-297
18.1.3 Cannabidiol
18.1.4 Dimiracetam
18.1.5 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 APX-3330
19.1.2 BR-297
19.1.3 Cannabidiol
19.1.4 Dimiracetam
19.1.5 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (USD/Unit) Trend 2021-2026
20.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Gross Profit Trend 2021-2026
21 Conclusion
